Therapeutic area
Psychiatry
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
7
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
50
Industry-sponsored
Recruiting Phase 3
69
Industry-sponsored
Recruiting Phase 4 (post-approval)
6
Industry-sponsored
Recent approvals
- Bysanti (Milsaperidone) · Vanda Pharms INC NovelFeb 20, 2026
To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
- Cobenfy (Trospium Chloride, Xanomeline Tartrate) · Bristol-Myers NovelSep 26, 2024
To treat schizophrenia
- Opipza (Aripiprazole) · Xiamen Lp Pharm CO Jul 22, 2024
- Exxua (Gepirone Hydrochloride) · Fabre Kramer NovelSep 22, 2023
To treat major depressive disorder
- Zurzuvae (Zuranolone) · Biogen NovelPriority reviewAug 4, 2023
To treat postpartum depression
- Uzedy (Risperidone) · Teva Apr 28, 2023
- Abilify Asimtufii (Aripiprazole) · Otsuka Apr 27, 2023
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- Teva1
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- RAP-219Phase 35 trials
Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure
- ACP-204Phase 34 trials
ACADIA Pharmaceuticals Inc. · Alzheimer's Disease Psychosis, Lewy Body Dementia Psychosis
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- KH607Phase 34 trials
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder
Largest recruiting Phase 3 trials
- A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07786454 · 1,120 participants (planned) · Start Oct 8, 2026 · Primary completion May 26, 2029
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Jacksonville, Florida; Orlando, Florida; Jamaica, New York · 4 sites in all
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07775300 · 1,000 participants (planned) · Start Aug 14, 2026 · Primary completion Dec 2028
Drug: Brenipatide; Placebo · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Phoenix, Arizona; Irvine, California · 170 sites in all
- A Study of Brenipatide in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07412756 · 1,000 participants (planned) · Start Feb 9, 2026 · Primary completion Feb 2028
Drug: Brenipatide; Placebo · For: Depressive Disorder, Major
Sites: Moorpark, California; Orange, California; New Haven, Connecticut · 180 sites in all
- 52-week Open Label Safety-Tolerability StudyPivotal-lookingRecruiting
LB Pharmaceuticals Inc.Industry
NCT07369154 · 900 participants (planned) · Start Apr 23, 2026 · Primary completion Dec 2028
Drug: LB-102 · For: Schizophrenia
Sites: Chandler, Arizona; Bentonville, Arkansas; Little Rock, Arkansas · 23 sites in all
- A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)Pivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07807865 · 900 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 18, 2030
Drug: ITI-1284 · For: Generalized Anxiety Disorder
Sites: Los Angeles, California; Miami, Florida; Brooklyn, New York
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06966401 · 850 participants (planned) · Start Apr 16, 2025 · Primary completion May 2029
Drug: NBI-1065845 · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Little Rock, Arkansas · 120 sites in all
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06559306 · 752 participants (planned) · Start Jul 25, 2024 · Primary completion Dec 30, 2026
Drug: Seltorexant; Placebo and 1 more · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 205 sites in all
- A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD TreatmentPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07856420 · 705 participants (planned) · Start Sep 29, 2026 · Primary completion Sep 20, 2030
Drug: JNJ-99245354; Placebo · For: Generalized Anxiety Disorder
Sites: Temecula, California; Miami, Florida; Springfield, Massachusetts · 4 sites in all
- Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaPivotal-lookingRecruiting
Reviva PharmaceuticalsIndustry
NCT05184335 · 690 participants (planned) · Start Jan 24, 2022 · Primary completion Feb 2025
Drug: Brilaroxazine · For: Schizophrenia
Sites: Phoenix, Arizona; Bentonville, Arkansas; Little Rock, Arkansas · 18 sites in all
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsPivotal-lookingRecruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT06931080 · 630 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 2027
Drug: EB-1020 (Centanafadine) 164.4 mg; EB-1020 (Centanafadine) 328.8 mg and 1 more · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Tokyo, Japan
More: Psychiatry news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.